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Both male and female rat growth plate cartilage cells possess estrogen receptors (ERs), but 17β-estradiol (E2) activates protein kinase C (PKC)
and PKC-dependent biological responses to E2 only in cells from female animals. PKC signaling can elicit genomic responses via mitogen
activated protein kinase (MAPK) and E2 has been shown to activate ERK MAPK in many cells, suggesting that MAPK may play a role in growth
plate chondrocytes as well. We tested if E2 increases MAPK activity and if so, whether the response is limited to female cells, if it is PKC-
dependent, and if the mechanism involves traditional ER pathways. We also determined the contribution of MAPK to the biological response of
growth plate chondrocytes and assessed the relative contributions of ERK, p38 and JNK MAPKs. Female rat costochondral cartilage cells were
treated with E2 and MAPK-specific activity determined in cell layer lysates. The mechanism of MAPK activation was determined by treating the
cells with E2 conjugated to bovine serum albumin (E2-BSA) to assess if membrane receptors were involved; stereospecificity was determined
using 17α-estradiol; PKC and phospholipase C (PLC) dependence was determined using specific inhibitors; and the ER agonist diethylstilbestrol,
the ER antagonist ICI 182780, and tamoxifen were used to assess the role of traditional ER pathways. E2 regulation of ERK1/2 MAPK was
assessed and the relative roles of ERK1/2, p38 and JNK MAPKs determined using specific inhibitors. E2 caused a rapid dose-dependent activation
of MAPK that was greatest in cells treated for 9 min with 10−9 M hormone; activity remained elevated for 3 h. E2's effect on MAPK was
stereospecific and comparable to that of E2-BSA. It was insensitive to DES and ICI 182780, dependent on PKC and PLC, blocked by tamoxifen
and it did not require gene transcription or translation. E2 had no effect on ERK1 or ERK2 mRNA or protein but it caused a rapid phosphorylation
of ERK1/2 at 9 min. Inhibition of ERK1/2 and p38 MAPK reduced the stimulatory effects of E2 on alkaline phosphatase activity and [
35S]-sulfate
incorporation. These results suggest that E2 regulates MAPK through a sex-specific membrane-mediated mechanism that does not involve
cytosolic ERs in a traditional sense and that ERK1/2 and p38 mediate the downstream biological effects of the hormone.
© 2006 Elsevier B.V. All rights reserved.Keywords: 17β-Estradiol; Sex-specificity; MAP kinase; Growth plate chondrocytes; ERK; p38; JNK1. Introduction
Estrogen (E2) regulates cells through classical steroid
hormone receptor mechanisms involving two receptors, ERα
and ERβ. Both receptors have been found in plasma membranes
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doi:10.1016/j.bbamcr.2006.02.010[19,32], suggesting that they might be involved in the
membrane-associated effects of the hormone. It is not clear
how membrane-associated ERs participate in the mechanism of
E2 action, however. Recent studies examining E2-dependent
phosphorylation of the ERK family of mitogen-activated
protein kinases (MAPKs), indicate that at least one mechanism
involves the formation of membrane-associated heterodimers of
ERα and ERβ [54].
Traditional cytosolic ERs are implicated in non-traditional
steroid hormone mechanisms [34], but non-ER pathways may
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++
[16,51,67], and in some instances this is unaffected by the ER
antagonist ICI 182780 [62,77]. Even when ERα and ERβ are
present, not all cells are responsive to the hormone. Although
both male and female cells possess nuclear receptors for ERα
and ERβ [2,44], some of the rapid responses to E2, including
activation of protein kinase C (PKC), are limited to cells from
female animals [2,16,44]. Moreover, PKC activation in female
cells is unaffected by the ER agonist diethylstilbestrol (DES) or
the ER antagonist ICI 182780, but it is blocked by tamoxifen,
which is a PKC inhibitor [46,60]. Estrogen that has been
conjugated with bovine serum albumin (E2-BSA) to prevent it
from crossing the plasma membrane [80], also activates PKC
and the biological responses that are dependent on PKC
activation, but does not affect these biological responses in male
cells [68,73]. The rapid effects of estrogen and E2-BSA are also
seen in breast cancer cell lines that lack ERα and ERβ [8].
These observations suggest that E2 activates PKC signaling by a
mechanism that is independent of these receptors in a traditional
sense and there is now evidence that novel G-protein coupled
receptors may be involved [26,53].
In female rat growth plate chondrocytes, E2 activates PKC
by rapidly increasing intracellular Ca++ concentration through a
capacitative entry mechanism [18], resulting in increased
phosphatidylinositol-dependent phospholipase C (PLC) activity
[58,70]. PKC activation can initiate a signaling cascade that
results in changes in gene expression through MAPK [11,38].
The fact that ERK1/2 MAPK family has been shown to be
activated by E2 in osteoblasts [64], embryonic fibroblasts, and
HeLa cells [28,29], suggests that it may also mediate effects of
the hormone on growth plate chondrocytes. It is not known,
however, if E2 regulates MAPK in a sex-specific manner,
whether MAPK is upstream or downstream of PKC activation,
or if the effects of E2 on MAPK are limited to ERK. E2 has also
been shown to activate p38 MAPK [62] and JNK MAPK [29],
which like ERK are expressed in chondrocytes [1,24,33,37,
39,49,61,76], raising the possibility that more than one form of
the enzyme plays a role. The purpose of this study was to
determine if the biological responses of growth plate chon-
drocytes to E2 involve one or more of these signaling pathways,
and if so whether they contribute to the sex-specific responses
of these cells to this steroid hormone.
2. Materials and methods
2.1. Reagents
The following reagents were purchased from Sigma Chemical Company (St.
Louis, MO): 17β-estradiol (E2), 17β-estradiol-bovine serum albumin (E2-BSA),
17α-estradiol, PD98059 (MEK inhibitor) [78], SB203580 (p38 inhibitor) [75],
SP600125 (JNK inhibitor) [10], chelerythrine and H-7 (PKC inhibitors) [23,25],
U73122 (phosphatidylinositol-specific PLC inhibitor) [4], actinomycin D
(transcription inhibitor), cycloheximide (translation inhibitor), and indometha-
cin (cyclooxygenase inhibitor). The Biotrack p42/p44 MAPK assay kit was
purchased from Amersham Pharmacia Biotech (Piscataway, NJ). Dulbecco's
modified Eagle's medium (DMEM) was obtained from Cellgro, Inc. (Atlanta,
GA), and fetal bovine serum (FBS) was purchased from Atlanta Biologicals
(Norcross, GA). The protein content of each sample was determined using the
bicinchoninic acid protein assay reagent [63] obtained from Pierce Chemical Co.(Rockford, IL). [32P]-ATP, [3H]-thymidine and [35S]-sulfate were obtained from
Perkin-Elmer (Boston, MA).
2.2. Chondrocyte cultures
The culture system used in this study has been described in detail previously
[6]. Chondrocytes were isolated from the resting zone (reserve zone) and growth
zone (prehypertrophic/upper hypertrophic cell zones) of the costochondral
cartilage of 125 g female and male Sprague–Dawley rats (approximately
1 month old). For each batch of cells, the costochondral cartilages were dissected
from 18 rats. The chondrocytes from these cartilages were combined and
cultured in DMEM containing 10% FBS and 50 μg/ml vitamin C in an
atmosphere of 5% CO2 and 100% humidity at 37 °C. Sharp dissection was used
to separate the cartilage layers. This is done under a dissecting scope, and the
zones can be visualized as differences in opacity. Resting zone chondrocytes are
primarily from the reserve zone, with some contamination from the uppermost
region of the proliferative cell zone. The central portion of the proliferative cell
zone is discarded to limit contamination. Growth zone cells are from the
prehypertrophic and upper hypertrophic cell zones. The lower hypertrophic cell
zone is discarded to limit contamination from osteoblasts. Some cells from the
lowermost region of the proliferative cell zone may be included in the growth
zone cell population. Fourth passage cells were used for all experiments, as prior
studies have shown retention of differential phenotype, including extracellular
matrix composition, plasma membrane and matrix vesicle fluidity and phospho-
lipid composition, responses to cytokines, growth factors, hormones, the vitamin
D metabolites 1α,25(OH)2D3 and 24R,25(OH)2D3, at this number of passages
(see [5,7] for examples). Moreover, the behavior of the fourth passage cells in
culture reflects the behavior of their zone of origin in vivo (see [14,15,56] for
examples). Fourth passage RC and GC cells express mRNAs for Sox-9,
aggrecan, cartilage oligomeric matrix protein (COMP), and type II collagen.
They also express type I collagen as an adaptation to monolayer culture but they
do not express osteocalcin. Typical of growth plate cartilage cells, they express
mRNA for alkaline phosphatase and activity of this enzyme is greater in the GC
cells, commensurate with their in vivo phenotype. While GC cells do possess
mRNA for type X collagen, SDS-polyacrylamide gel electrophoresis of the
extracellular matrix indicates that they do not produce the protein.
Each experiment was conducted so that there were six separate cultures for
each variable tested, all cultures coming from one batch of cells. Each
experiment was repeated multiple times, using cells from a different batch each
time. Because our cells come from animals and not from an established cell line,
there are differences in baseline values due to differences in media, the team
doing the dissection, etc. To ensure that data from any one experiment were
comparable to results from other experiments, we compared the results using
treatment/control ratios. Using this approach, we had sufficient power in each
experiment for statistical analysis (described below).
At confluence, media were removed and replaced with experimental
medium containing estrogen at the concentrations indicated below. Although E2-
BSA is known to contain some free E2, we did not remove free E2 from the E2-
BSA used in the present study prior to its addition to the cultures. We previously
showed that responses of the growth plate chondrocytes to unfiltered E2-BSA
were comparable to those seen in chondrocytes treated with filtered E2-BSA
[73].
2.3. Regulation of MAPK by E2 and E2-BSA
2.3.1. MAPK-specific activity
MAPK-specific activity was determined using the Biotrack p42/p44
MAPK assay kit following the manufacturer's directions. Confluent cultures
of male and female resting zone and growth zone chondrocytes were treated
with 10−10 to 10−7 M E2 for 9 or 90 min. To determine time course, cultures
were treated with 10− 9 M E2 for 9, 90, 180 or 270 min. Stereospecificity was
determined by treating female cells with E2 or its stereoisomer 17α-estradiol
(10−10 to 10−7 M) for 9 min. Female growth zone and resting zone cells were
also treated with E2-BSA (10
−10 to 10−7 M) to determine if the increase in
MAPK was membrane mediated. Control cultures were treated with media
containing the ethanol vehicle. After the appropriate incubation period, cell
layers were washed with PBS and lysed in solubilization buffer [50 mm Tris–
HCl (pH 7.5), 150 mm NaCl, 5 mm EDTA, and 1% Nonidet P-40] for 30 min
Fig. 1. Effect of 17β-estradiol onMAPK-specific activity of confluent growth zone chondrocyte cultures isolated from female and male rats. Cultures were treated with
10−10 to 10−7 M 17β-estradiol for 9 min (A, female cells; C, male cells), or for 9–270 min with 10−9 M 17β-estradiol (B and D). MAPK-specific activity was
measured in cell layer lysates as described in Materials and methods. Values are from a representative experiment and are the mean±S.E.M. for six independent
cultures. The experiment was repeated two additional times with nearly identical results. *P<0.05 vs. control (A and C) or 9 min (B and D); #P<0.05 vs. 17β-
estradiol treatment (B and D).
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activity.
2.3.2. ERK1/2 phosphorylation
To determine if 17β-estradiol regulated the levels of ERK1/2 protein or
activated MAPK activated by tyrosine phosphorylation [11], cell culture lysates
were examined by Western blot using specific antibodies to non-phosphorylated
and phosphorylated p42/p44 MAPK. Cell culture lysates were prepared from
confluent, fourth passage growth zone cell cultures that had been treated for 9 or
90 min with 10−9 to 10−7 M E2 and were resolved on 10% SDS-polyacrylamide
gels. Blots of the gels were probed with 1:5000 dilutions of rabbit polyclonal
antibodies to phosphorylated p42/p44 or non-phosphorylated p42/p44 (Promega
Corp., Madison, WI), followed by 1:5000 dilutions of alkaline phosphatase-
conjugated anti-rabbit IgG1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA).
Immunoreactive bands were visualized using the nitro blue tetra-zolium/5-
bromo-4-chloro-3-indolyl-phosphate reagent (Sigma).
2.3.3. Northern blot analysis
To quantify the effects of E2 on mRNA levels for ERK1 and ERK2, we
performed Northern blot analysis. Chondrocytes were treated with 10−10 to
10−7 M E2 for 9, 90 and 270 min. Total RNA for untreated and E2-treated female
growth zone and resting zone chondrocytes was isolated with TRIzol, quantified
spectrophotometrically, separated on a 1% denaturing agarose gel, and
transferred to a positively charged nylon membrane (Ambion, Inc.) with the
Turboblotter System (Schleicher and Schuell, Inc., Keene, NH). Northern blots
were hybridized with ERK1, ERK2, and glyceraldehyde-3-phosphate dehydro-
genase-strippable 32P-labeled anticoding RNA probes using the NorthernMax
Kit (Ambion, Inc.). ERK1 and ERK2 DNA templates were synthesized from
sequenced RT-PCR products amplified with modified antisense primers with the
T7 promoter sequence, 5′-TAA TAG GAC TCA CTA TAG GGA GG-3′,
attached to the 5′-end of the antisense primers. Anticoding RNA probes weresynthesized with the Strip-EZ T7 Kit (Ambion, Inc.). Northern blots were
analyzed with a PhosphorImager (Molecular Dynamics, Inc., Sunnyvale, CA).
2.3.4. Requirement for gene expression and protein synthesis
To determine whether new gene expression or protein synthesis is required
for E2-dependent stimulation of MAPK activity, female growth zone and resting
zone chondrocytes were treated with 1, 10, or 100 μM actinomycin D to block
transcription or with 1, 10, or 100 μM cycloheximide to block translation [48].
These doses were selected based on previous studies using the costochondral
growth plate chondrocyte model [72].
2.3.5. Requirement for nuclear estrogen receptors
To determine if traditional nuclear estrogen receptor mechanisms are re-
quired for activation of MAPK, female growth zone and resting zone chondro-
cytes were incubated with an estrogen receptor antagonist, ICI 182780 or with
an estrogen receptor agonist, diethylstilbestrol (DES) [74]. Confluent cultures
were treated with vehicle or 10−9 M E2 in the presence and absence of 10
−9 to
10−7 M antagonist or agonist. MAPK-specific activity was measured at 9 min.
2.3.6. Protein kinase C
17β-Estradiol mediates its effects on growth zone cells via PKC signaling
pathways [70]. To determine whether E2-dependent activation of MAPK
involves PKC, PKC activity was blocked using chelerythrine (0.1, 1, or 10 μM)
or with 10−9 to 10−7 M tamoxifen, as described by us previously [8,60]. Female
growth zone and resting zone chondrocyte cultures were incubated for 9 and
90 min in control medium or medium containing 10−9 M E2 in the presence and
absence of the inhibitor.
2.3.7. Phospholipase C
PLC mediates the effects of E2 on PKC in growth zone cell cultures [70]. Its
involvement in the effect of E2 on MAPK was assessed by using U73122, an
384 J. McMillan et al. / Biochimica et Biophysica Acta 1763 (2006) 381–392inhibitor of phosphatidylinositol specific (PI)-PLC [4], at 0.1, 1.0, or 10 μM.
Female growth zone and resting chondrocytes were incubated for 9 and 90 min
in control medium or medium containing 10−9 M E2, with or without U73122
and MAPK activity was determined.
2.4. Role of MAPK in mediating the biological response to
17β-estradiol
Female growth zone and resting zone chondrocytes were used for these
experiments. To block the effects of ERK1/2 MAPK, cells were treated with the
MEK inhibitor PD98059 [78]. Two sets of experiments were performed.
Cultures were treated with vehicle (control) or 10−9 M E2 in the presence of 1,
10, or 100 μM PD98059. In the second set of experiments, cultures were treated
with 0 or 100 μM PD98059 in the presence of vehicle or 10−10 to 10−7 M E2. To
block the effects of p38 MAPK, cells were treated with vehicle or 10−9 M E2 in
the presence of 10−7 to 10−5 M SB203580 [75]. To block the effects of JNK
MAPK, cells were treated with vehicle or 10−9 M E2 in the presence of 10
−7 to
10−5 M SP600125 [10]. In each case, cultures were incubated with E2± inhibitor
for 24 h.
2.4.1. [3H]-thymidine incorporation
17β-Estradiol inhibits [3H]-thymidine incorporation by resting zone and
growth zone chondrocytes [40]. To determine whether this response is mediated
by MAPK, DNA synthesis was estimated by measuring [3H]-thymidine
incorporation into trichloroacetic acid-insoluble cell precipitates as described
previously [40]. Quiescence was induced by incubating preconfluent cultures
for 48 h in DMEM containing 1% FBS. The medium was then replaced with
DMEM containing 1% FBS alone (control), E2, and inhibitor (or appropriate
vehicles). Two hours before harvest, [3H]-thymidine was added.
2.4.2. Alkaline phosphatase-specific activity
17β−Estradiol stimulates alkaline phosphatase-specific activity in growth
zone and resting zone chondrocyte cultures [40]. To determine whether this
effect was mediated by MAPK, confluent cultures were treated with 17β-
estradiol and inhibitor for 24 h. Alkaline phosphatase [orthophosphoric
monoester phosphohydrolase, alkaline (EC 3.1.3.1)]-specific activity was
measured in cell layer lysates as a function of release of para-nitrophenol
from para-nitrophenylphosphate at pH 10.2, as described previously [9,22,57].
2.4.3. Proteoglycan sulfation
17β-Estradiol causes an increase in [35S]-sulfate incorporation in growth
zone chondrocyte cultures [40]. To determine whether this is mediated by
MAPK, proteoglycan synthesis was assessed by measuring [35S]-sulfate
incorporation by confluent cultures as described by us previously [42,47]. At
confluence, cells were treated with fresh medium containing E2 plus inhibitor for
24 h. Four hours before harvest, 50 μl DMEM containing 18 μCi/ml [35S]-
sulfate and 0.814 mM carrier sulfate were added to each culture. At harvest, the
conditioned media were removed, the cell layers (cells and matrix) were
collected, and the amount of [35S]-sulfate incorporated was determined as a
function of cell layer protein.
2.5. Statistical management of data
For each experiment, each value represents the mean±S.E.M. of the cell
layers of six independent cultures. Statistical significance was determined by
ANOVA. Bonferroni's modification of the t test was used for post hoc testing.
P<0.05 was considered significant. Each experiment was repeated two or more
times to ensure the validity of the data. The data presented are from a single
representative experiment. Effects of E2 on MAPK were similar in growth zone
and resting zone chondrocyte cultures. For this reason, only the results for
growth zone cells are presented as figures for many of the experiments below.Fig. 2. Effect of E2 on ERK1 and ERK2 in rat costochondral growth plate
chondrocytes. (A) Confluent cultures of resting zone (RC) cells and growth
zone (GC) cells were treated with vehicle or 10−10 to 10−7 M E2 for 9 min.
mRNA was isolated and levels of ERK1 and ERK2 mRNA determined via
Northern blots using GAPDH as a control. (B) Growth zone chondrocytes were
treated for 9 or 90 min with vehicle or 10−9 to 10−7 M E2. Levels of phos-
phorylated ERK1/2 and total ERK were determined by Western blot analysis.3. Results
MAPK activity was sensitive to 17β-estradiol, but only in
female cells. In female growth zone cells, E2 caused a biphasicincrease in MAPK-specific activity that was greatest at 10−9 M
(Fig. 1A). The effect was maximal at 9 min, although activity
remained elevated over controls through 180 min (Fig. 1B). In
contrast to the stimulatory effects of E2 on female cells, male
cells exhibited no response either as a function of E2
concentration (Fig. 1C), or time (Fig. 1D). Resting zone cells
responded to E2 in a similar manner, with peak activity in
female cells at 10−9 M hormone and at 9 min and no effect on
MAPK in male cells (data not shown).
The effect of E2 on MAPK was nongenomic. Growth zone
and resting zone chondrocytes both expressed mRNA for
ERK1/2 (p42/p44) based on RT-PCR (data not shown) and
Northern blot analysis (Fig. 2A), and the levels of expression
were similar in both types of cells. Treatment with E2 had no
effect on mRNA levels for either form of the enzyme in either
type of cell. Inhibition of gene transcription with actinomycin D
or of protein synthesis with cycloheximide had no effect on the
increase caused by E2 (data not shown). Western blots of total
ERK1/2 demonstrated that the total amount of this MAPK was
unchanged after treatment of female growth zone cells for either
9 or 90 min (Fig. 2B). However, phosphorylated ERK1/2 was
increased and peak levels were seen in cells treated with 10−9 M
for 9 min. The effect on resting zone cells was comparable (data
not shown).
E2 activated MAPK via a stereospecific mechanism. The
inactive stereoisomer 17α-estradiol had no effect on MAPK
activity in female growth zone cells (Fig. 3A) or female resting
zone cells (Fig. 3B). The increase in MAPK was also
Fig. 3. Effect of 17α-estradiol, 17β-estradiol, and 17β-estradiol-BSA on
MAPK-specific activity of confluent growth zone and resting zone chondrocyte
cultures isolated from female rats. Confluent, female growth zone (GC) cells
were treated with 10−10 M to 10−7 M estrogen for 90 min (A). Identical
experiments were performed with female resting zone (RC) cells (B). MAPK-
specific activity was measured in cell layer lysates as described in Materials and
methods. Values are means±S.E.M. for six independent cultures. Data presented
are from one experiment. The experiment was repeated two additional times
with nearly identical results. *P<0.05 vs. control; #P<0.05 vs. 17β-estradiol
treatment.
Table 1
Effect of ER agonist diethylstilbestrol (DES) and the ER antagonist ICI 182780
on MAP kinase-specific activity in cultures treated for 9 min with 10−9 M 17β-
estradiol (E2) or 17β-estradiol-BSA (E2-BSA)
Treatment MAP activity (pmoles PO4/μg protein/minute)
DES Control E2 E2-BSA
0 4.11±0.49 6.56±0.60* 7.15±0.44*
10−9 M 4.20±0.48 6.37±0.63* 6.63±0.65*
10−8 M 5.04±0.13 7.31±0.53* 6.69±0.52*
10−7 M 4.83±0.17 6.30±0.29* 6.88±0.31*
ICI 182780
0 4.72±0.30 6.23±0.30* 6.30±0.16*
10−9 M 4.84±0.25 6.24±0.30* 6.13±0.31*
10−8 M 5.16±0.43 7.06±0.33* 5.69±0.59*
10−7 M 4.62±0.41 6.11±0.23* 6.17±0.19*
Data are means±S.E.M. for 6 independent cultures and are from one of two
experiments, both with comparable results. *P<0.05, with estrogen vs. without
estrogen (Control).
Fig. 4. Effect of tamoxifen on estrogen-dependent MAPK-specific activity in
confluent growth zone chondrocyte cultures isolated from female rats. Cells
were treated for 90 min with 10−9 M to 10−7 M tamoxifen in the presence of
10−9 M 17β-estradiol or 17β-estradiol-BSA. Values are means±S.E.M. for six
independent cultures. Data are from one of two experiments, both with
comparable results. *P<0.05 vs. control; #P<0.05 vs. tamoxifen treatment.
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stimulatory effect on enzyme activity in growth zone and resting
zone cell cultures as was seen following treatment with the non-
conjugated form of the hormone.
MAPK activation did not involve traditional estrogen
receptor pathways. Treatment of growth zone cells (Table 1)
or resting zone cells (data not shown) with the ER agonist DES
or the ER antagonist ICI 182780 had no effect on E2-dependent
MAPK activity. However, both E2 and E2-BSA work via a
tamoxifen-dependent mechanism. Tamoxifen caused a dose-
dependent reduction in activation of MAPK by E2 or E2-BSA
but sensitivity to the inhibitor differed (Fig. 4). The effect of
tamoxifen on E2-treated growth zone cells was less robust than
on cultures treated with E2-BSA. This was also true for resting
zone cells (data not shown).
E2 increased MAPK by a mechanism involving PKC and
PLC. Treatment of female growth zone cells with the PKC-
inhibitor chelerythrine caused a dose-dependent decrease in
MAPK-specific activity (Fig. 5A). This effect was evident at all
time points examined (Fig. 5B). Similarly, treatment of the
cells with the PLC-inhibitor U73122 inhibited E2-dependent
MAPK in a dose-dependent manner (Fig. 5C) at all time points(Fig. 5D). This was the case for resting zone cells as well (data
not shown).
DNA synthesis in growth plate chondrocyte cultures was
mediated by a mechanism involving ERK1/2. Treatment of the
cells with PD98059 caused a dose-dependent decrease in [3H]-
thymidine incorporation in female growth zone cells (Fig. 6A)
and resting zone cells (data not shown). The inhibitory effect of
E2 on DNA synthesis was affected by PD98059 only at the
highest concentration of inhibitor. The inhibitory effect of
PD98059 on DNA synthesis was additive with that of E2 on
DNA synthesis was additive with that of E2 (Fig. 6B),
suggesting that different mechanisms were involved.
ERK1/2 MAPK-mediated biological responses of female
growth zone chondrocytes to E2. PD98059 blocked the
stimulatory effect of E2 on alkaline phosphatase activity. The
inhibitor had no effect on enzyme activity in control cultures of
female growth zone cells, but reduced the E2-dependent
increase in a dose-dependent manner (Fig. 7A) and at all
stimulatory doses of the hormone (Fig. 7B). PD98059 reduced
the effect of E2 on [
35S]-sulfate incorporation as well. The
Fig. 5. Effect of chelerythrine and U73122 on estrogen-dependent MAPK-specific activity in cultures of confluent growth zone chondrocytes from female rats. Cells
were treated for 90 min with 0.1, 1, or 10 μM chelerythrine (A) or U73122 (B) in the presence of 10−9 M 17β-estradiol. Time course experiments (B, chelerythrine; D,
U73122) were also performed at time points of 9, 90, and 180 min. In these experiments, cultures were treated with either 10−9 M 17β-estradiol, inhibitor, or with
10-9 M 17β-estradiol and inhibitor to examine any combined effects. Values are the mean±S.E.M. for six cultures from one experiment. *P<0.05 vs. control; #P<0.05
vs. inhibitor treatment.
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stimulatory concentrations of the hormone (Fig. 7D), although
this may have been due at least in part to a general regulation of
proteoglycan synthesis via this signaling pathway.
Part of the E2 effect on growth plate chondrocytes was via
p38 MAPK. Inhibition of this family of MAPKs reduced [3H]-
thymidine incorporation in growth zone cells and at the highest
concentration, was additive with E2 (Fig. 8A), suggesting that
separate mechanisms were involved. SB203580 also blocked
the stimulatory effect of E2 on alkaline phosphatase (Fig. 8B)
and on [35S]-sulfate incorporation (Fig. 8C). The inhibitor
altered response of resting zone cells in a similar manner (data
not shown).
DNA synthesis was mediated by JNK MAPK (Fig. 9A).
SP600125 caused a dose-dependent decrease in [3H]-thymidine
incorporation in growth zone cells and at the highest
concentration, blocked the response of the cells to E2.
SP600125 had no effect on alkaline phosphatase activity (Fig.
9B) or [35S]-sulfate incorporation (Fig. 9C) in control cultures
or in cultures treated with E2. Similar responses were observed
in resting zone cells (data not shown).
4. Discussion
This study shows that MAPK is regulated by E2 in growth
plate chondrocytes in a sex-specific manner that does notdepend on the state of maturation of the cell in the
endochondral pathway. Both resting zone cells and growth
zone cells exhibited comparable responses to the hormone, as
noted previously for PKC [70]. However, only female cells
exhibited an increase in MAPK activity when treated with E2.
The increase depended on increases in PKC, based on
inhibition by two PKC inhibitors, chelerythrine and tamox-
ifen. The increase also depended on PLC, based on inhibition
by the phosphatidylinositol-specific inhibitor U73122. Both
PKC and PLC have been shown to be stimulated by E2 only
in female cells [58,70]. In addition, these prior studies also
showed that E2 increases PKC via a PLC-dependent pathway
[16], suggesting that E2 acts on MAPK via a PLC-PKC
signaling pathway.
As noted previously for PLC and PKC, the effects of E2 on
MAPK are membrane-dependent based on the observation that
E2-BSA elicits a comparable response. E2-BSA has been shown
to bind to surface receptors for 17β-estradiol [71], and remains
extracellular [81]. Further support that specific receptors are
involved is the observation that activation of MAPK was
stereospecific; only treatment with 17β-estradiol and not 17α-
estradiol resulted in increased enzyme activity. Our findings are
commensurate with those in other laboratories demonstrating
that E2 acts via membrane receptors, including ERα and ERβ
[19,31,32,45]. While the results indicate that E2 acts through a
membrane receptor-mediated mechanism, cytosolic estrogen
Fig. 6. Effect of PD98059 on [3H]-thymidine incorporation in pre-confluent
cultures of female rat growth zone (GC) chondrocytes. Cells were treated for
24 h with 1, 10 or 100 μM PD98059 in the presence of 10−9 M 17β-estradiol
(A). Alternatively, cells were treated with 10−9 to 10−7 M 17β-estradiol in the
presence of 100 μM PD98059 (B). Values are means±S.E.M. for six
independent cultures. Data are from one experiment of two experiments, both
with comparable results. *P<0.05 vs. control; #P<0.05 vs. treatment with
10−9 M 17β-estradiol or 100 μM PD98059.
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46 kDa variant of ERα have been shown to interact directly
with PKCα in osteoblasts, resulting in phosphorylation of c-Src
[12].
It is unlikely that traditional nuclear receptor pathways were
involved. The effects of the hormone were rapid, occurring
within 9 min, and they did not require new gene transcription or
protein synthesis. Moreover, we found that the ER agonist DES
and the ER antagonist ICI 182780 had no effect. This is also the
case for E2-dependent activation of PKC [60]. In contrast to the
inability of DES or ICI 182780 to alter the response to E2,
tamoxifen blocked the activation of MAPK. Tamoxifen may act
both as an agonist or antagonist of E2 action depending on the
response being assayed [13,30]. It is unlikely that it acted via a
classical ER pathway in the growth zone cells, however.
Tamoxifen is a known PKC inhibitor [46,60] and it blocks the
stimulatory effects of 1α,25(OH)2D3 on PKC in both male and
female growth zone chondrocytes [60]. Thus, it is probable that
it inhibited the effects of E2 through its inhibition of PKC. These
observations indicate that sex-specific increases in MAPK
occur via non-traditional pathways, and suggest the possibility
of additional receptors for the hormone. Novel receptors for E2that mediate rapid actions of the hormone have recently been
identified [20,36], including a receptor expressed only in female
cells [17].
Our results show that increased MAPK activity may result
from more than one form of the enzyme. At least part of the sex-
specific increases in MAPK measured in this study was due to
rapid activation of ERK1/ERK2. Western blots indicated that
total ERK1/ERK2 was unaffected, but E2 treatment caused a
rapid dose-dependent phosphorylation of ERK1/2. Northern
analysis supported the lack of a genomic response as there was
no change in ERK1 or ERK2 mRNA. Our results are in
agreement with those of Doolen et al. [16], demonstrating that
PKC and ERK1/2 MAPK are activated in a sex-specific manner
in rat intestinal cells. Other investigators have reported that in
human osteoblasts, ERK1/2 MAPK is activated by E2 via non
sex-specific mechanisms involving ERα [28,29]. Failure to find
sexually dimorphic responses may be due to differences in
experimental design, differences in cell sources, or differences
in species. It should be noted, however, that female-specific
increases in E2-dependent PKC have also been reported for
human articular chondrocytes [27].
Our results show that effects of E2 on post-natal growth plate
chondrocytes are mediated by at least two forms of MAPK.
Both PD98059 and SB203580 blocked the E2-dependent
stimulation of alkaline phosphatase activity, a hallmark of
differentiated growth zone cells. Previous studies have shown
the importance of ERK1/2 and p38 for the differentiation of
prechondrocytes [52] and the maturation of micromass
chondrocyte cultures [16]. This suggests that the two forms of
the enzyme work in concert and that E2 induces endochondral
maturation in the female growth plate through these interactive
pathways. Cross talk between ERK1/2 and p38 pathways has
been reported in chondrocytes in response to a variety of
regulatory factors [43,66]. Our results support this by
demonstrating that the two MAPK families regulate comparable
phenotypic responses in the cells.
PD98059 is a widely used inhibitor of ERK family MAPKs.
It acts upstream of ERK, preventing its phosphorylation by
inhibiting MEK. We did not attempt to assess which isoform of
ERK is responsible for the E2-response. Similarly, there are four
mammalian p38 genes, all of which are expressed during
endochondral development [65]. Because we used a general
inhibitor of p38 [75], we were not able to determine which of
the p38 isoforms was responsible. It may be that the cooperative
effects of ERK1/2 and p38 are due to specific species of each
MAPK family as noted for other kinase families.
PD98059, and to a lesser extent SB203580, also reduced the
stimulatory effect of E2 on proteoglycan production, based on
the inhibition in [35S]-sulfate incorporation. Sulfation of
glycosaminoglycans in proteoglycan aggregate is a terminal
step in their production, occurring after aggrecan and link
protein synthesis and glycosylation, a processing requiring
numerous enzymes, which themselves must be synthesized and/
or activated. Thus, our observation suggests that one or more of
these E2-regulated steps are mediated by mechanisms involving
transcriptional control via pathways that may be independent of
traditional ERs.
Fig. 7. Effect of PD98059 on alkaline phosphatase-specific activity and [35S]-sulfate incorporation in confluent cultures of female rat growth zone (GC) chondrocytes.
Cells were treated with 1, 10 or 100 μM PD98059 in the presence of 10−9 M 17β-estradiol (A, C). Alternatively, cells were treated for 24 h with 10−9 to 10−7 M 17β-
estradiol in the presence of 100 μM PD98059 (B, D). Values are means±S.E.M. for six independent cultures. Data are from one experiment of two experiments, both
with comparable results. *P<0.05 vs. control; #P<0.05 vs. treatment with 10−9 M 17β-estradiol or 100 μM PD98059.
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support previous reports using prechondrocyte murine cell
models. ERK1/2 and p38 are required for proteoglycan
production in cultures of ATDC5 cells [76]. Others [3,79]
have shown that inhibition of p38 signaling blocks expression
of type X collagen, suggesting that this MAPK is required for
chondrocyte hypertrophy. Moreover, p38 inhibition is needed
for endochondral development of primary mouse mesenchymal
cells [65,66]. In the post-natal rat growth plate, hypertrophy is
associated with a reduction in proteoglycan production. Thus,
our results suggest that ERK1/2 and p38 control post-
proliferative prehypertrophic cells in the zone of maturation
when matrix production is intact and alkaline phosphatase
enriched matrix vesicles are being released into the extracellular
matrix.
JNK MAPK has been shown to be regulated by E2 in other
systems [29]. However, inhibition of JNK had no effect on
alkaline phosphatase activity or [35S]-sulfate incorporation in
the growth plate chondrocyte cultures. This suggests that factors
controlling these two parameters are not mediated by the JNK
signaling pathway.
We showed previously that inhibition of PKC blocks DNA
synthesis in growth plate cells, as do treatment with E2 or E2-
BSA [68]. Both estrogen compounds activate PKC in resting
zone and growth zone cells. In contrast, E2 stimulates
proliferation of breast cancer cells [8] and articular chondro-
cytes [27] via mechanisms involving traditional receptors. Thismay explain why inhibition of PKC-dependent MAPK activity
with PD89059, SB203580, or SP600125 did not have a clearly
demonstrable effect on DNA synthesis in the growth plate
chondrocytes in response to E2. MAPK pathways are involved
in regulation of DNA synthesis, however, as all three inhibitors
decreased [3H]-thymidine incorporation in control cultures to
some degree, and one or more of the MAPKs may have
contributed to the inhibition caused by E2.
There appears to be a relationship between the length of time
MAPK remains active and the overall phenotypic response of
chondrocytes to factors that regulate MAPK activation. In
studies using the RCS chondrocyte cell line to study FGF
signaling, rapid transient increases in MAPK were associated
with proliferation, whereas persistent elevation in MAPK was
associated with chondrocyte growth arrest and differentiation
[52]. We found that MAPK activity in general, and ERK1/2
activation specifically, was increased within 9 min. While
effects of E2 on ERK were rapid, it is possible that p38 and JNK
were activated at a later time. Peak MAPK activity was at 9 min,
but activity remained elevated for 180 min. This is long enough
for the signaling pathways to modulate existing enzymes within
the cells and to initiate new gene expression leading to matrix
synthesis and endochondral maturation.
In summary, our findings support our previous findings and
the observations of others that membrane-dependent signaling
is initiated by E2 via activation of PKC and PKC-dependent
MAPK. One of the MAPKs contributing to the rapid increase in
Fig. 8. Effect of SB203580 on [3H]-thymidine incorporation (A), alkaline
phosphatase-specific activity (B) and [35S]-sulfate incorporation (C) in cultures
of female rat growth zone chondrocytes. Cells were treated for 24 h with 10−7
to 10−5 M SB203580 in the presence of 10−9 M 17β-estradiol. Values are
means±S.E.M. for six independent cultures. Data are from one experiment of
two experiments, both with comparable results. *P<0.05 vs. control; #P<0.05
vs. 17β-estradiol treatment.
Fig. 9. Effect of SP600125 on [3H]-thymidine incorporation (A), alkaline
phosphatase-specific activity (B) and [35S]-sulfate incorporation (C) in cultures
of female rat growth zone chondrocytes. Cells were treated for 24 h with 10−7
to 10−5 M SP600125 in the presence of 10−9 M 17β-estradiol. Values are
means±S.E.M. for six independent cultures. Data are from one experiment of
two experiments, both with comparable results. *P<0.05 vs. control; #P<0.05
vs. 17β-estradiol treatment.
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the stimulatory effects of E2 on alkaline phosphatase and [
35S]-
sulfate incorporation. Inhibition of p38 also reduces the
stimulatory effects of E2 on these parameters, suggesting that
there is cross-talk between these two signaling pathways.
The ERK1/2 MAPK pathway studied here is operative in
female cells but not in male cells and does not appear to be
mediated by traditional ER mechanisms. Male rat costochondral
growth plate chondrocytes possess cytosolic estrogen receptors
based on specific binding of radiolabeled E2 but there are fewer
cytosolic receptors than in female cells [41]. Assuming that only
a subset of these receptors participates in direct PKC activation
[35], failure to observe an effect of E2 in male cells may simplyreflect a subthreshold response. It is more likely, however, that
one or more components of the membrane-initiated signaling
pathway is absent in male cells, as we have noted for
membrane-mediated activation of PKC by 1α,25(OH)2D3 in
resting zone cells [56]. Alternatively, the membrane receptor(s)
initiating the signaling cascade may be is present in reduced
amounts or absent completely.
Longitudinal bone growth is regulated by estrogen via
traditional estrogen receptor pathways [21] in addition to the
MAPK signaling cascades described in this paper. At least part
of the estrogen effect is sex-specific [50,59]. Our results suggest
that MAPK signaling is involved, but other factors may play a
390 J. McMillan et al. / Biochimica et Biophysica Acta 1763 (2006) 381–392role. Aromatase-deficient males lack the growth arrest typical of
normal males, due to their inability to convert testosterone to
estrogen. This may also be a contributing factor to the results
presented here. Female chondrocytes express higher levels of
aromatase than male cells and produce greater amounts of 17β-
estradiol [69]. In contrast, male chondrocytes convert testoster-
one to dihydrotestosterone via 5-alpha reductase type I [69].
Thus, local concentrations of the sex steroids, as well as
systemic levels of the hormones may contribute to the sex-
specific regulation of these cells.
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